期刊文献+

胰岛素样生长因子-2、血管内皮生长因子受体-2、血小板源生长因子受体和类肝素酶-1在肾上腺皮质癌中的表达及其意义

Relationship of IGF-2,VEGFR-2,PDGFR and HPA expressions in adrenal cortical carcinoma
下载PDF
导出
摘要 目的探讨胰岛素样生长因子-2(IGF-2)、血管内皮生长因子受体-2(VEGFR-2)、血小板源生长因子受体(PDGFR)和类肝素酶-1(HPA)在肾上腺皮质癌(ACC)中的表达及其临床意义。方法选取经手术治疗且具有完整的临床、病理资料的肾上腺皮质肿瘤存档石蜡标本37例,其中良性组20例,恶性组(ACC组)17例。采用免疫组化技术检测良、恶性肾上腺皮质肿瘤中IGF-2、VEGFR-2、PDGFR和HPA的表达情况。结果 IGF-2在ACC组中呈高表达(76.47%),在良性组中表达低(5.00%),ACC组与良性组之间IGF-2的表达有极显著性差异(P<0.01);VEGFR-2在ACC组中呈高表达(76.47%),在良性组中表达较低(25.00%),ACC组与良性组之间VEGFR-2的表达有显著性差异(P<0.05);PDGFR在ACC组中表达的阳性率为(17.64%),在良性组中为(20.00%),PDGFR在ACC组中的表达与在良性组中的表达无显著性差异(P>0.05)。HPA在ACC组中的表达为(94.12%),良性组中为(15.00%),两者之间有显著性差异(P<0.05)。结论 IGF-2、VEGFR-2和HPA在ACC中的高表达为抗肿瘤血管生成治疗在ACC中的应用,提供了相应的理论依据。 Objective To investigate the expressions of IGF-2,VEGFR-2,PDGFR and HPA in adrenal cortical carcinoma(ACC) and to discuss their clinical significance.Methods 37 patients were divided into two groups,20 in the benign group and 17 in the malignant group(adrenal cortical carcinoma,ACC group).The adrenal cortical neoplasm specimens removed from these patients were examined with immunohistochemistrical method to detect the expressions of IGF-2,VEGFR-2,PDGFR and HPA.Results IGF-2,VEGFR-2,and HPA expressed highly in the ACC group(76.47%,76.47%,and 94.12% respectively) and lowly in the benign group(5.00%,25.00%,and 15.00% respectively),with significant difference(P0.05).PDGFR expressions were not significantly different between the ACC group and benign group(P0.05).Conclusion The high expressions of IGF-2,VEGFR-2,and HPA in ACC contribute to tumor angiogenesis,which provide theoretical evidences for anti-angiogenesis regime of ACC.
出处 《现代泌尿外科杂志》 CAS 2011年第5期395-398,共4页 Journal of Modern Urology
基金 上海市自然科学基金资助(No.09ZR1418500) 上海市教委科研创新项目(No.11YZ58)
关键词 肾上腺皮质癌 胰岛素样生长因子2(IGF-2) 血管内皮生长因子受体2(VEGFR-2) 血小板源生长因子受体(PDGFR) 类肝素酶-1(HPA) 免疫组织化学 adrenal cortical carcinoma insulin-like growth factor-2 vascular endothelial growth factor receptor-2 platelet-derived growth factor receptor Heparanase-1 immunohistochemistry
  • 相关文献

参考文献14

  • 1WANDOLOSKI M, BUSSEY KJ, DEMEURE MJ. Adrenocortical cancer[J]. Surg Clin North Am, 2009,89(5) : 1255-1267.
  • 2LACROIX A. Approach to the patient with adrenocortical carcinoma [ J ]. J Clin Endocrinol Metab, 2010, 95 ( 11 ): 4812-4822.
  • 3KIRSCHNER LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope[J]. J Clin Endocrinol Metab, 2006,91(1):14-21.
  • 4ALLOLIO B, FASSNACHT M. Clinical review: Adrenocortical carcinoma: clinical update[J]. J Clin Endoerinol Metab, 2006, 91(6) :2027-2037.
  • 5BRIX D, ALLOLIO B, FENSKE W, et al. Laparoseopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients[J]. Eur Urol, 2010, 58(4) : 609-615.
  • 6TERZOLO M, ANGELI A, FASSNACHT M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma[J].N Engl J Med, 2007, 356(23): 2372-2380.
  • 7FASSNACHT M, HAHNER S, POLAT B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocort-ical carcinoma[J]. J Clin Endocrinol Metab, 2006, 91(11) : 4501-4504.
  • 8FASSNACHT M, KREISSL MC, WEISMANN D, et al. New targets and therapeutic approaches for endocrine malignancies [J]. Pharmacol Ther, 2009, 123(1) :117-141.
  • 9WEBER MM, AUERNHAMMER CJ, KIESS W, et al. Insulin- like growth factor receptors in normal and tumorous adult human adrenocortical glands[J]. Eur J Endocrinol, 1997, 136(3):296- 303.
  • 10BARLASKAR FM, SPALDING AC, HEATON JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenoeortical carcinoma [J].J Clin Endocrinol Metab, 2009, 94(1): 204-212.

二级参考文献81

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:626
  • 2Li X R,Ponten A,Aase K,et al.PDGF-C is a new proteaseactivated ligand for the PDGF α-receptor.Nat Cell Biol,2000,2(5):302~309
  • 3Bergsten E,Uutela M,Li X R,et al.PDGF-D is a specific,protease-activated ligand for the PDGF β-receptor.Nat Cell Biol,2001,3(5):512~516
  • 4Fredriksson L,Li H,Eriksson U.The PDGF family:four gene products form five dimeric isoforms.Cytokine Growth Factor Rev,2004,15(4):197~204
  • 5Uutela M,Lauren J,Bergsten E,et al.Chromosomal location,exon structure,and vascular expression patterns of the human PDGFC and PDGFC genes.Circulation,2001,103(18):2242~2247
  • 6Pietras K,Sjoblom T,Rubin K,et al.PDGF receptors as cancer drug targets.Cancer Cell,2003,3(5):439~443
  • 7Tallquist M,Kazlauskas A.PDGF signaling in cells and mice.Cytokine Growth Factor Rev,2004,15(4):205~213
  • 8Henriksen R,Funa K,Wilander E,et al.Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.Cancer Res,1993,53(19):4550~4554
  • 9Garofalo A,Naumova E,Manenti L,et al.The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.Clin Cancer Res,2003,9(9):3476~3485
  • 10Machida S,Saga Y,Takei Y,et al.Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).Int J Cancer,2005,114(2):224~229

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部